甘露聚糖肽治疗老年慢性阻塞性肺疾病稳定期疗效评价

Effect of Mannatide Capsules in Treating Stable Stage of Chronic Obstructive Pulmonary Disease

目的观察甘露聚糖肽胶囊用于老年慢性阻塞性肺疾病(COPD)稳定期的临床效果。方法将156例住院患者随机均分为试验组和对照组,各78例。在给予吸氧、平喘、解痉、抗感染(必要时)等常规治疗基础上,试验组给予甘露聚糖肽胶囊,对照组给予泛福舒,治疗后随访6个月。结果试验组COPD急性发作次数、发作持续天数均减少,但组间无显著性差异(P>0.05)。治疗结束后,两组患者症状积分较治疗前均有改善(P<0.05),试验组改善更显著(P<0.01);治疗结束后,两组患者第1秒用力呼气量/用力肺活量(FEV1/FVC)、第1秒用力呼气量(FEV1)、第1秒用力呼气量占预计值百分比(FEV1%)均得到改善(P<0.05),且试验组FEV1显著改善(P<0.01)。试验组CD4+,CD4+/CD8+,Ig A及补体C3水平较治疗前均显著提高(P<0.05),CD8+显著降低(P<0.05);对照组Ig A明显升高(P<0.05),CD4+,CD4+/CD8+及补体C3均较治疗前有所上升(P>0.05),CD8+无明显变化(P>0.05);组间比较,治疗后试验组CD4+,CD4+/CD8+及补体C3较对照组升高(P<0.05),CD8+显著降低(P<0.05);两组Ig A含量均升高,但差异无统计学意义(P>0.05)。结论甘露聚糖肽胶囊能全面提高COPD患者的免疫功能,改善临床症状和肺功能。

Objective To observe the clinical efficacy of Mannatide Capsules in the treatment of elderly patients with stable stage of chronic obstructive pulmonary disease （COPD）. Methods 156 inpatients with COPD were randomly divided into the experimental group （n=78） and the control group（n =78）. On the basis of the conventional therapy such as oxygen inhalation, relieving asthma, spasmoly- sis and anti- infection（in necessity）, the experimental group was administrated with Mannatide Capsules and the control group was given Broncho- vaxom. The follow up lasted for 6 months after therapy. Results The experimental group had less frequency and short onset persistent duration of AECOPD than the control group, but without statistically significant difference between the two groups（P 〉 0.05）; the symptom scores after treatment in the two groups were improved compared with those before treatment（P 〈 0. 05）, but the efficacy of the experimental group was more significant than that of the control group（P 〈 0.01）; FEVx/FVC, FEV1 and FEV1% after treatment in the two groups were improved compared with those before treatment（P 〈 0.05）, moreover FEV1 in the experiment group was improved significantly（P 〈 0.01）. the levels of CD3＋CD4＋, CD3＋CD4＋/CD3＋CD8＋, IgA and C3 after treatment in the experiment group were significantly improved than those before treatment（ P 〈 0. 05）, and the CD3 ＋CD8＋ level was significantly decreased（ P 〈 0.05）; the IgA level in the control group was significantly increased（P 〈 0.05）, and the levels of CD3＋CD4＋, CD3＋CD4＋/CD3＋CD8＋ and C3 were increased than those before treatment（P 〉 0.05）, while the CD3＋CD8＋ level had no obvious difference（P 〉 0. 05）; com- pared with the control group, the levels of CD3＋CD4＋, CD3＋CD4＋/CD3＋CD8＋ and C3 in the experiment group were significant increased （P 〈 0.05） and the CD3＋CD8＋ level was significantly decreased（P 〈 0.05）, while the IgA level in the two groups were increased, but the difference was not statistically significant（ P 〉 0. 05）. Conclusion Mannatide Capsules can allroundly improve the immune function, improve the clinical symptoms and lung function, in the patients with COPD.